4basebio Plc - Holding(s) in Company
PR Newswire
LONDON, United Kingdom, November 15
TR-1: Standard form for notification of major holdings
| NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i | ||||||
| 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: | 4basebio PLC | |||||
| 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) | ||||||
| Non-UK issuer | ||||||
| 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) | ||||||
| An acquisition or disposal of voting rights | X | |||||
| An acquisition or disposal of financial instruments | ||||||
| An event changing the breakdown of voting rights | ||||||
| Other (please specify) iii: acting in concert under DTR 5.2.1(a) | X | |||||
| 3. Details of person subject to the notification obligation iv | ||||||
| Name | Elevage Medical Technologies Holdings, LLC (as indirect parent shareholder under DTR 5.1.2 and 5.2.1(e) and indirect holder of voting rights under DTR 5.2.1(a)) | |||||
| City and country of registered office (if applicable) | Wilmington, Delaware, United States | |||||
| 4. Full name of shareholder(s) (if different from 3.) v | ||||||
| Name | Fort Aggregator, LP (as direct shareholder) and the Prudential Assurance Company Limited (as the other party to the agreement under DTR5.2.1(a)) | |||||
| City and country of registered office (if applicable) |
| |||||
| 5. Date on which the threshold was crossed or reached vi: | 13 November 2024 | |||||
| 6. Date on which issuer notified (DD/MM/YYYY): | 14 November 2024 | |||||
| 7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer (8.A + 8.B) vii | |||
| Resulting situation on the date on which threshold was crossed or reached | 29.9 | 0 | 29.9 | 4,627,741 | ||
| Position of previous notification (if applicable) | N/A | N/A | N/A | |||
| 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii | |||||||||
| A: Voting rights attached to shares | |||||||||
| Class/type of sharesISIN code (if possible) | Number of voting rights ix | % of voting rights | |||||||
| Direct (DTR5.1) | Indirect (DTR5.2.1) | Direct (DTR5.1) | Indirect (DTR5.2.1) | ||||||
| Ordinary shares of €1.00 each under DTR 5.2.1(e)ISIN: GB00BMCLYF79 | 0 | 2,666,667 | 0 | 17.2% | |||||
| Ordinary shares of €1.00 each under DTR 5.2.1(a)ISIN: GB00BMCLYF79 | 1,961,074 | 0 | 12.7% | ||||||
| SUBTOTAL 8. A | 4,627,741 | 29.9% | |||||||
| B 1: Financial Instruments according to DTR5.3.1R (1) (a) | |||||||||
| Type of financial instrument | Expiration date x | Exercise/ Conversion Period xi | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
| SUBTOTAL 8. B 1 | |||||||||
| B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) | |||||||||
| Type of financial instrument | Expiration date x | Exercise/ Conversion Period xi | Physical or cash Settlement xii | Number of voting rights | % of voting rights | ||||
| SUBTOTAL 8.B.2 | |||||||||
| 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) | ||||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii | ||||
| Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv | X | |||
| Name xv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
| Chain 1 in respect of Fort Aggregator LP: | ||||
| Elevage Medical Technologies Holdings, LLC | 17.2% | 17.2% | ||
| Elevage Medical Technologies GP, LLC | 17.2% | 17.2% | ||
| Fort Aggregator, LP | 17.2% | 17.2% | ||
| Chain 2 in respect of the Prudential Assurance Company Limited | ||||
| M&G plc | 12.7% | 12.7% | ||
| M&G Group Regulated Entity Holding Company Limited | 12.7% | 12.7% | ||
| M&G Group Limited | 12.7% | 12.7% | ||
| M&G FA Limited | 12.7% | 12.7% | ||
| M&G Investment Management Limited | 12.7% | 12.7% | ||
| 10. In case of proxy voting, please identify: | ||||
| Name of the proxy holder | ||||
| The number and % of voting rights held | ||||
| The date until which the voting rights will be held | ||||
| 11. Additional information xvi | ||||
| Fort Aggregator, LP and the Prudential Assurance Company Limited have concluded pursuant to DTR 5.2.1(a). As such, the disclosure in sections 7, 8 and 9 of this form reflects their aggregated position. A separate notification will be made on behalf of M&G plc in respect of the Prudential Assurance Company Limited’s shareholding. | ||||
| Place of completion | Wilmington, Delaware, United States |
| Date of completion | 13 November 2024 |
